BioMarin Pharmaceutical Quarterly Income Statement
NASDAQ: BMRNHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BioMarin Pharmaceutical revenue and earnings
In the quarter ended Jun 30, 2026, BioMarin Pharmaceutical generated $989.7 million in revenue, up 19.9% from the same quarter a year earlier. Net income was $44.8 million (-81.4% year over year), for a net margin of 4.5% versus a median of 13.8% in the prior 5 quarters. Gross margin was 79.5% (down from 81.8%) and operating margin 11.2%.
Diluted earnings per share came in at $0.23, down from $1.23.
Summary generated from market data by MetaCap's automated system. Methodology
BioMarin Pharmaceutical income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 989.71M | 766.21M | 874.57M | 776.13M | 825.41M | 745.14M | 747.31M | 745.74M | 712.03M | 648.83M | 646.21M | 581.33M |
| Revenue growth (YoY) | +19.91% | +2.83% | +17.03% | +4.08% | +15.92% | +14.84% | +15.65% | +28.28% | +19.61% | +8.79% | +20.22% | +15.04% |
| Cost of Revenue | 202.79M | 195.00M | 275.71M | 140.09M | 150.09M | 151.56M | 136.14M | 188.46M | 130.46M | 125.18M | 137.93M | 128.04M |
| Gross Profit | 786.91M | 571.21M | 598.86M | 636.05M | 675.32M | 593.59M | 611.17M | 557.28M | 581.57M | 523.65M | 508.28M | 453.29M |
| Operating Expenses | 675.99M | 441.57M | 643.47M | 682.74M | 398.43M | 369.69M | 449.77M | 443.39M | 461.12M | 435.19M | 481.00M | 422.76M |
| Research & Development | 206.95M | 178.80M | 192.41M | 409.48M | 161.31M | 158.73M | 173.51M | 184.90M | 183.79M | 204.99M | 206.25M | 191.31M |
| Selling, General & Admin | 395.55M | 258.29M | 446.21M | 268.42M | 232.28M | 206.12M | 266.61M | 253.48M | 263.03M | 225.91M | 259.51M | 215.77M |
| Operating Income | 110.92M | 129.64M | -44.61M | -46.69M | 276.89M | 223.89M | 161.41M | 113.89M | 120.45M | 88.46M | 27.28M | 30.52M |
| Interest Expense | 60.73M | 9.57M | 2.78M | 2.58M | 2.39M | 2.39M | 2.58M | 2.97M | 3.57M | 3.55M | 6.10M | 3.78M |
| Pretax Income | 61.38M | 141.20M | -27.15M | -26.32M | 297.87M | 238.09M | 169.64M | 134.44M | 132.14M | 105.55M | 19.33M | 41.67M |
| Income Tax | 16.62M | 35.68M | 19.42M | 4.42M | 57.34M | 52.40M | 44.70M | 28.36M | 24.96M | 16.89M | -1.05M | 1.29M |
| Net Income | 44.76M | 105.53M | -46.57M | -30.74M | 240.53M | 185.69M | 124.94M | 106.08M | 107.17M | 88.66M | 20.38M | 40.38M |
| Net Income growth (YoY) | -81.39% | -43.17% | -137.28% | -128.98% | +124.43% | +109.43% | +513.22% | +162.72% | +91.25% | +74.35% | — | — |
| EPS (Basic) | 0.23 | 0.55 | -0.24 | -0.16 | 1.25 | 0.97 | 0.66 | 0.56 | 0.56 | 0.47 | 0.11 | 0.21 |
| EPS (Diluted) | 0.23 | 0.54 | -0.22 | -0.16 | 1.23 | 0.95 | 0.65 | 0.55 | 0.55 | 0.46 | 0.10 | 0.21 |
| Shares Outstanding (Basic) | 193.42M | 192.50M | — | 192.03M | 191.91M | 190.97M | — | 190.43M | 190.11M | 188.87M | — | 188.22M |
| Shares Outstanding (Diluted) | 194.47M | 197.67M | — | 192.03M | 197.09M | 196.47M | — | 197.15M | 200.50M | 199.26M | — | 191.17M |
| EBITDA | 208.56M | 146.05M | -24.17M | -28.20M | 295.45M | 245.96M | 185.01M | 132.90M | 146.91M | 115.81M | 54.14M | 56.21M |
| Gross Margin | 79.51% | 74.55% | 68.47% | 81.95% | 81.82% | 79.66% | 81.78% | 74.73% | 81.68% | 80.71% | 78.66% | 77.97% |
| Operating Margin | 11.21% | 16.92% | -5.10% | -6.02% | 33.55% | 30.05% | 21.60% | 15.27% | 16.92% | 13.63% | 4.22% | 5.25% |
| Net Margin | 4.52% | 13.77% | -5.33% | -3.96% | 29.14% | 24.92% | 16.72% | 14.22% | 15.05% | 13.66% | 3.15% | 6.95% |
This table shows 12 quarterly periods of BioMarin Pharmaceutical's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow BMRN's reporting calendar. What is a income statement?